search
Back to results

Gluteal Turnover Flap for Closure of the Perineal Wound After Abdominoperineal Resection for Rectal Cancer (BIOPEX2)

Primary Purpose

Wound Heal, Abdominoperineal Resection, Rectal Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Gluteal turnover flap
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Wound Heal

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • clinical diagnosis of primary rectal cancer or recurrent rectal cancer
  • scheduled for abdominalperineal resection
  • older then 18 years

Exclusion Criteria:

  • intersphincteric APR
  • (biological) mesh placement
  • extended resections (sacral resection except for coccyx resection, (posterior) exenteration)
  • severe systemic diseases affecting wound healing except diabetes (i.e. renal failure requiring dialysis, liver cirrhosis, and immune compromised status like HIV), collagen disorders (i.e. Marfan)
  • enrolment in other trials with overlapping primary endpoint.

Sites / Locations

  • Amsterdam UMC, location AMCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Primary closure

Gluteal turnover flap

Arm Description

Primary perineal closure after extralevator abdomino perineal resection

Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection

Outcomes

Primary Outcome Measures

Perineal wound healing rate 30 days
The primary endpoint of the study is the percentage of uncomplicated perineal wound healing defined as a Southampton wound score of less than Il at 30 days postoperatively.

Secondary Outcome Measures

Perineal wound healing
Southampton wound score
Re-intervention or re-admission rate
Need tor re-intervention or re-admission related to pre-sacral abscess or either perineal wound problems.
Perineal hernia rate
lncidence of symptomatic and asymptomatic perineal hernia
Health-related quality of life
questionnaires: The 5-level EQ-5D version (EQ-5D-5L)
Quality of Life in cancer patients
questionnaires: European Organization for Research and Treatment for Cancer Quality of Life Questionnaire (C30-QL2, CR29)
Generic quality of Life
questionnaires: Short Form Survey (SF36)
Urogenital Distress
questionnaires: Urogenital Distress Inventory (UDI-6)
Incontinence scale
questionnaires:Incontinence Impact Questionnaire short form (IIQ-7)
Urogenital function
questionnaires: international index of erectile function (IIEF)
Female sexual distress
questionnaires: Female sexual distress scale (FSDS-R)

Full Information

First Posted
June 10, 2019
Last Updated
July 1, 2019
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
search

1. Study Identification

Unique Protocol Identification Number
NCT04004650
Brief Title
Gluteal Turnover Flap for Closure of the Perineal Wound After Abdominoperineal Resection for Rectal Cancer
Acronym
BIOPEX2
Official Title
Gluteal Turnover Flap for Closure of the Perineal Wound After Abdominoperineal Resection for Rectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Unknown status
Study Start Date
June 28, 2019 (Actual)
Primary Completion Date
May 1, 2022 (Anticipated)
Study Completion Date
November 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: About 700 patients per year undergo an abdominoperineal resection (APR) for distal rectal cancer (Dutch Colorectal Audit 2016).Neoadjuvant (chemo)radiotherapy is often used to further improve locoregional control. Morbidity after APR is substantial and mainly consisting of perineal wound problems in about 35% of the patients. lf primary healing of the perineal wound after APR doesn't occur, secondary healing can take up to one year, and there is even a small proportion of patients in whom a chronic perineal wound or fistula persists after one year. During this long period, intensive wound care is necessary. This results in a heavy burden on both patient and health care resources. Objective: The high morbidity rate of the perineal wound has resulted in a continuing discussion on how to close the perineal defect after APR. Our research group recently published the BIOPEX-study (NL42094.018.12), in which 104 patients were randomized between primary perinea! wound closure and biological mesh closure of the pelvic floor after APR with preoperative radiotherapy for rectal cancer. Similar uncomplicated perineal wound healing rate at 30 days (Southampton wound score < 2) was found: 63% versus 66%, respectively. The hypothesis behind this negative trial result is related to the perineal dead space between the skin and the biological mesh. Fluid will accumulate in this dead space with the risk of secondary contamination and abscess formation, leading to wound dehiscence and purulent discharge. Autologous tissue flaps have been suggested to improve perineal wound healing based on several cohort studies. At least in the Netherlands, these flaps are used only for selected patients with the large defects and highest risk of wound problems, because of the more extensive surgery with added surgical trauma and operative time, and associated donor site morbidity. For these reasons, primary perineal closure (control arm of BIOPEX) is still the standard of care in the Netherlands. A gluteal turnover flap (GT flap) is a small transposition flap trom the unilateral adjacent perineal skin and subcutaneous fat, which is flipped into the perineal dead space, and stitched with the de-epithelialised dermis to the contralateral pelvic floor remnant. Subsequently, the perineal subcutaneous fat and skin are closed over the flap in the midline, thereby not adding a donor site scar. A small pilot study trom our group showed that this is a promising solution for routine perineal closure after APR. Study design: In this multicenter single blinded study, eligible patients will be randomized between pelvic floor reconstruction using a GT flap (intervention arm) and primary closure of the perineal defect (standard arm). The perineal wound healing will be evaluated at 14 days and 1, 3, and 6 months post-operatively using the Southampton wound scoring system by an independent observer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wound Heal, Abdominoperineal Resection, Rectal Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Primary closure
Arm Type
No Intervention
Arm Description
Primary perineal closure after extralevator abdomino perineal resection
Arm Title
Gluteal turnover flap
Arm Type
Experimental
Arm Description
Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection
Intervention Type
Procedure
Intervention Name(s)
Gluteal turnover flap
Intervention Description
Link to procedure: https://www.youtube.com/watch?v=u7_vH2_1ZZc
Primary Outcome Measure Information:
Title
Perineal wound healing rate 30 days
Description
The primary endpoint of the study is the percentage of uncomplicated perineal wound healing defined as a Southampton wound score of less than Il at 30 days postoperatively.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Perineal wound healing
Description
Southampton wound score
Time Frame
14 days, 3 and 6 months postoperatively
Title
Re-intervention or re-admission rate
Description
Need tor re-intervention or re-admission related to pre-sacral abscess or either perineal wound problems.
Time Frame
1,3,6 months
Title
Perineal hernia rate
Description
lncidence of symptomatic and asymptomatic perineal hernia
Time Frame
1,3,6 months
Title
Health-related quality of life
Description
questionnaires: The 5-level EQ-5D version (EQ-5D-5L)
Time Frame
1,3,6 months
Title
Quality of Life in cancer patients
Description
questionnaires: European Organization for Research and Treatment for Cancer Quality of Life Questionnaire (C30-QL2, CR29)
Time Frame
1,3,6 months
Title
Generic quality of Life
Description
questionnaires: Short Form Survey (SF36)
Time Frame
3,6 months
Title
Urogenital Distress
Description
questionnaires: Urogenital Distress Inventory (UDI-6)
Time Frame
1,3,6 months
Title
Incontinence scale
Description
questionnaires:Incontinence Impact Questionnaire short form (IIQ-7)
Time Frame
1,3,6 months
Title
Urogenital function
Description
questionnaires: international index of erectile function (IIEF)
Time Frame
1,3,6 months
Title
Female sexual distress
Description
questionnaires: Female sexual distress scale (FSDS-R)
Time Frame
1,3,6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: clinical diagnosis of primary rectal cancer or recurrent rectal cancer scheduled for abdominalperineal resection older then 18 years Exclusion Criteria: intersphincteric APR (biological) mesh placement extended resections (sacral resection except for coccyx resection, (posterior) exenteration) severe systemic diseases affecting wound healing except diabetes (i.e. renal failure requiring dialysis, liver cirrhosis, and immune compromised status like HIV), collagen disorders (i.e. Marfan) enrolment in other trials with overlapping primary endpoint.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah Sharabiany, MD
Phone
0031653663288
Email
s.sharabiany@amsterdamumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Gijsnert Musters, MD, PhD
Email
g.d.musters@amsterdamumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pieter Tanis, Prof. MD. Phd
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amsterdam UMC, location AMC
City
Amsterdam-Zuidoost
State/Province
Noord-Holland
ZIP/Postal Code
1105AZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Sharabiany, MD
Phone
0031653663288
Email
s.sharabiany@amsterdamumc.nl

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32703182
Citation
Sharabiany S, Blok RD, Lapid O, Hompes R, Bemelman WA, Alberts VP, Lamme B, Wijsman JH, Tuynman JB, Aalbers AGJ, Beets GL, Fabry HFJ, Cherepanin IM, Polat F, Burger JWA, Rutten HJT, Bosker RJI, Talsma K, Rothbarth J, Verhoef C, van de Ven AWH, van der Bilt JDW, de Graaf EJR, Doornebosch PG, Leijtens JWA, Heemskerk J, Singh B, Chaudhri S, Gerhards MF, Karsten TM, de Wilt JHW, Bremers AJA, Vuylsteke RJCLM, Heuff G, van Geloven AAW, Tanis PJ, Musters GD. Perineal wound closure using gluteal turnover flap or primary closure after abdominoperineal resection for rectal cancer: study protocol of a randomised controlled multicentre trial (BIOPEX-2 study). BMC Surg. 2020 Jul 23;20(1):164. doi: 10.1186/s12893-020-00823-7.
Results Reference
derived

Learn more about this trial

Gluteal Turnover Flap for Closure of the Perineal Wound After Abdominoperineal Resection for Rectal Cancer

We'll reach out to this number within 24 hrs